Canada Markets closed
  • S&P/TSX

    +103.34 (+0.52%)
  • S&P 500

    +23.02 (+0.57%)
  • DOW

    +141.43 (+0.43%)

    +0.0004 (+0.0540%)

    +0.15 (+0.20%)

    -188.88 (-0.49%)
  • CMC Crypto 200

    -3.31 (-0.53%)

    +1.00 (+0.05%)
  • RUSSELL 2000

    -3.22 (-0.18%)
  • 10-Yr Bond

    -0.0150 (-0.42%)
  • NASDAQ futures

    +49.00 (+0.37%)

    -0.10 (-0.52%)
  • FTSE

    +56.16 (+0.74%)
  • NIKKEI 225

    +274.88 (+0.99%)

    -0.0005 (-0.07%)

VitaDAO Closes $4.1M Funding Round With Pfizer Ventures for Longevity Research

Join the most important conversation in crypto and web3! Secure your seat today

VitaDAO, a decentralized autonomous organization (DAO) focused on raising funds for research on extending human life, has closed a $4.1 million funding round with Pfizer Ventures and several others.

VitaDAO was started in 2021 by Tyler Golato of decentralized biotech protocol Molecule to fund longevity research. According to the organization, it boasts a community of over 9,000 "enthusiasts, researchers and contributors," and deployed over $3.5 million to projects researching diseases of aging, cellular biology and repairing age-related damage to the body in 2022.

The latest funding round includes pharmaceutical giant Pfizer Ventures; venture fund Shine Capital; investment group L1 Digital; decentralized science organizations BeakerDAO and Spaceship DAO; and longevity enthusiasts including former Coinbase Chief Technology Officer Balaji Srinivasan and Retro Biosciences' Joe Betts-LaCroix. Previous investors include Ethereum co-founder Vitalik Buterin.

According to VitaDAO, Pfizer is the first pharmaceutical company to vote on DAO proposals and participate in the incubation and commercialization of VitaDAO projects.

Proceeds from the latest round will go toward funding longevity research projects and building out VitaDAO's first biotech startup, slated to be announced in the first quarter of 2023. In addition, the group plans to invest further in the "commercialization and licensing" of its non-fungible token (NFT) intellectual property (IP) through its partnership with Molecule.

VitaDAO's deal flow steward Laurence Ion said that several projects funded by VitaDAO have moved to the next stages of development, including clinical trials with Mantis Photonics, which seeks to diagnose Alzheimer's Disease through retinal imaging.

"There's a move away in medicine to solve the symptoms of aging," said Todd White, operations steward at VitaDAO. "There's a lot of discussion around 'is aging a disease?' A lot of people are of the mindset now that aging and a lot of the diseases of aging ... can actually be resolved."

The group is governed by its native VITA token and holders can vote on what projects to support, while a group of "stewards" helps to "facilitate" the execution of those proposals, said White.

Ion told CoinDesk that with its democratic governance structure, the group aims to move beyond physical locations and is thinking about "a potential future sovereignty network."

"I think we need a new paradigm," he said. "We want to be a community as big as some countries and as resourceful as some countries."

Crypto enthusiasts have long been into longevity science and delaying human aging. Coinbase CEO Brian Armstrong funded a company called NewLimit in December 2021 to "cure aging," while former Ripple chief technology officer and current Stellar co-founder Jed McCaleb founded the Astera Institute to fund longevity studies.

White said the overlap between the crypto industry and the longevity research field is no coincidence. "If you think about how crypto started, it was about breaking down barriers and fixing a system that they perceived as broken. Well, the same applies in longevity."

"There's a lot more innovation and a lot more enthusiasm to try new things coming from the crypto community," he added.